Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda

SETTING: In 2005, in response to the increasing prevalence of rifampicin-resistant tuberculosis (RR-TB) and poor treatment outcomes, Rwanda initiated the programmatic management of RR-TB, including expanded access to systematic rifampicin drug susceptibility testing (DST) and standardised treatment....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The international journal of tuberculosis and lung disease 2020-03, Vol.24 (3), p.329-339
Hauptverfasser:	Ngabonziza, J-C. S., Habimana, Y. M., Decroo, T., Migambi, P., Dushime, A., Mazarati, J. B., Rigouts, L., Affolabi, D., Ivan, E., Meehan, C. J., Van Deun, A., Fissette, K., Habiyambere, I., Nyaruhirira, A. U., Turate, I., Semahore, J. M., Ndjeka, N., Muvunyi, C. M., Condo, J. U., Gasana, M., Hasker, E., Torrea, G., de Jong, B. C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitubercular Agents - therapeutic use Delay Delayed Diagnosis Diagnostic systems Empirical analysis Humans Mdr-Tb Diagnosis Mdr-Tb Programmatic Management Mdr-Tb Treatment Microbial Sensitivity Tests Mortality Multidrug resistance Multidrug resistant organisms Mycobacterium tuberculosis Reduction Retrospective Studies Rifampin Rifampin - therapeutic use Rwanda Rwanda - epidemiology Time-to-Treatment Tuberculosis Tuberculosis, Multidrug-Resistant - diagnosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!